SCHEMBL721356

SCHEMBL721356

COc1ccc(-c2cc3nccc(Cl)c3o2)c(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
AMY1A P0DUB6 3/20 0.36
CYP1A1 P04798 3/20 0.36
CYP1B1 Q16678 3/20 0.36
GAK O14976 2/20 0.34
RIPK2 O43353 1/20 0.34
COQ8A Q8NI60 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723084 0.89 QPCT (0.41) KDM4EALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL722554 0.87 KDM4E (0.44) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL10267556 0.82 ALDH1A1 (0.44) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL15172930 0.82 ALDH1A1 (0.48) KDM4EALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL721335 0.82 SYK (0.45) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL723271 0.79 PDE4A (0.50) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL723470 0.79 EHMT2 (0.41) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL18348254 0.79 F2RL3 (0.34) KDM4EALDH1A1MAPTSMN1; SMN2CYP1A2
SCHEMBL721337 0.78 CYP1A1 (0.44) KDM4EALDH1A1MAPTHPGDMAPK1
SCHEMBL723457 0.77 CYP1A1 (0.36) ALDH1A1CYP1A2CYP3A4CYP2C19NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB KDM4E 1009/4885ALDH1A1 1457/4885LMNA 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.